Enhancer deletions of the SHOX gene as a frequent cause of short stature: the essential role of a 250 kb downstream regulatory domain

J Chen,1 G Wildhardt,2 Z Zhong,1 R Röth,1 B Weiss,1 D Steinberger,2 J Decker,2 W F Blum,3 G Rappold1

ABSTRACT
Background: Mutations and deletions of the homeobox transcription factor gene SHOX are known to cause short stature. The authors have analysed SHOX enhancer regions in a large cohort of short stature patients to study the importance of regulatory regions in developmentally relevant genes like SHOX.

Methods: The authors tested for the presence of copy number variations in the pseudoautosomal region of the X chromosome in 735 individuals with idiopathic short stature and compared the results to 58 cases with Leri–Weill syndrome and 100 normal height controls, using fluorescence in situ hybridisation (FISH), single nucleotide polymorphism (SNP), microsatellites, and multiplex ligand dependent probe amplification (MLPA) analysis.

Results: A total of 31/735 (4.2%) microdeletions were identified; almost half of these (13/29; 45%) involve enhancer sequences and leave the SHOX gene intact. These deletions were absent in 100 control persons.

Conclusion: The authors conclude that enhancer deletions in the SHOX gene region are a relatively frequent cause of growth failure in patients with idiopathic short stature and Leri–Weill syndrome. The data highlights the growing recognition that regulatory sequences are of crucial importance in the genome when diagnosing and understanding the aetiology of disease.

Short stature is a developmental, multifactorial condition with a strong genetic component. Three per cent of the population are defined as being short. Short stature can have many different causes, a multitude of which are genetic. Several large scale genome wide association studies have recently determined variants that affect susceptibility to disease and identified a total of 54 validated single nucleotide polymorphism (SNP) variants with an influence on height. However, in total these large scale studies only pinpointed candidate genes of relatively minor effect within each locus, explaining only a small proportion of the phenotypic variance in the normal population, and thus accounting together for little more than 5% of our height (0.4 cm per “increasing” allele).

Although mutations in several genes have been reported that cause pronounced short or tall stature with a drastic effect on height (10–30 cm per “mutant” allele), this normally accounts for only a very small proportion of patients with short stature. So we are left with the fact that for the vast majority of short individuals with a height below −2 standard deviations scores (SDS), no causing defects are known, clinically termed as “idiopathic” short stature.

One of the more prevalent causes of short stature was shown to derive from a defect in a developmental gene on the X chromosome, SHOX (short stature homeobox gene; MIM 312865). Defects in the coding region of SHOX have been demonstrated in individuals with different short stature syndromes including Leri–Weill, Langer and Turner syndrome (MIM 127300), but mutations are also found in patients with idiopathic short stature (ISS) (MIM 300582).

Regulatory elements residing either 5’ or 3’ of a gene can be sites of mutations in genetic disease and interfere with the normal expression of a gene. Some of these elements—defined as enhancers or repressors—can lie a considerable distance away from the coding portion of a gene. Enhancer elements can act upstream and downstream of a gene and function only in certain cell types. In concert with transcription factors that bind to these enhancer sequences, they play a role in achieving the appropriate level of gene expression. Defects in enhancer sequences have as yet only rarely been identified, and like promoter mutations, are considered to play only a relatively minor role in disease.

Comparative genomic analysis has previously identified evolutionarily conserved non-coding DNA elements, termed CNE, several hundred kilobases downstream of the SHOX gene in patients with Leri–Weill syndrome (LWS). Three of these elements have subsequently been shown to act as enhancers in the chicken limb bud and five elements as enhancers in the neural tube. To establish the frequency and significance of long range regulatory elements also in individuals with idiopathic short stature (ISS), we have analysed the DNA of 735 patients with ISS and compared these results to 58 patients with a clinical manifestation of LWS and 100 controls.

SUBJECTS AND METHODS
The study was conducted in accordance with the principles of the Declaration of Helsinki/Good Clinical Practice and was approved by the ethics committees of the participating institutions. Investigators obtained written informed consent...
from the participants’ parent(s) or legal guardian(s) before conducting study related procedures.

**Study subjects**

We studied 740 unrelated pre-pubertal children with ISS from 14 countries: Belgium (n = 61), Canada (n = 59), Croatia (n = 54), Czech Republic (n = 57), France (n = 60), Germany (n = 144), Hungary (n = 29), India (n = 7), Netherlands (n = 2), Poland (n = 49), Russia (n = 6), Spain (n = 107), Turkey (n = 61), and USA (n = 54). Inclusion criteria were: chronological age ≥3 years and pre-pubertal (males: genital stage Tanner 1 and testses ≤2 ml; females: breast stage Tanner 1); height ≤3rd centile of the local reference range or height ≤10th centile with height velocity ≤25th centile; bone age ≤10 years for boys and ≤8 years for girls; no growth hormone (GH) deficiency or GH resistance; no chronic disease; and no known growth influencing medications.

Our study also included 67 patients with LWS from eight different European countries: Germany (n = 37), Austria (n = 1), Croatia (n = 4), France (n = 10), Italy (n = 2), Netherlands (n = 8), Spain (n = 4), and Sweden (n = 1). The control cohort consisted of 100 individuals of European origin with normal stature. We used a combination of DNA sequencing, microsatellite analysis, fluorescence in situ hybridization (FISH), and multiplex ligand dependent probe amplification (MLPA),16 to search for copy number variations in the PAR1 region showing the position of the SHOX gene (fig 1).

We have also screened the 735 ISS patients for homozygosity of two markers in direct vicinity of the SHOX gene (DXYS201 and CAII),14 to pinpoint SHOX containing deletions. In all individuals where all two markers were homozygous, FISH analysis was carried out, and in 18 individuals a deletion of the SHOX gene was demonstrated by FISH. In these 18 individuals, MLPA was also carried out additionally as a further confirmation for the SHOX containing deletions. MLPA analysis was also carried out in DNA of 58 LWS patients who had been previously tested for the presence or absence of the SHOX gene and in DNA of 100 control individuals.

In total, MLPA analysis demonstrated a deletion in the pseudoautosomal region of 33/201 tested ISS patients, with peaks at a ratio <0.5 as compared to normal controls (fig 2). Deletion sizes ranged between 52 kb and several megabases of DNA and no duplications were detected. Thirty-three of the 33 microdeletions included the SHOX gene. A comparison of the results to the control cohort showed that two of the deletions (no. 27 and 28; see fig 2) represent polymorphisms as they were also detected in two control individuals (fig 2). Among the 31 remaining microdeletions of the PAR region, eight ISS patients presented deletions including only the enhancer sequences, CNE7, CNE8 and/or CNE9 (no. 24–26, 29–33; fig 2). Three of

**Figure 1**

Schematic representation of the PAR1 region showing the position of evolutionarily conserved non-coding DNA elements (CNEs), microsatellites and cosmids that were used for deletion mapping.15 The SHOX gene is indicated in red and resides between 505.1 and 540.1 kb from the telomere (NCBI build 125, March 2006). The CNEs and microsatellites used for deletion mapping are shown above the scale bar. CNEs are indicated in green; CNE4, CNE5 and CNE9 with a star symbol have shown enhancer activity in the developing chicken limb bud.16 CNE3, CNE4, CNE5, CNE7 and CNE9 have previously shown enhancer activity in the chicken neural tube.15 Microsatellites are indicated in blue. The SHOX exons and the cosmids contig used for deletion mapping are shown below the scale bar. Cosmid 34F05 (LLN0YCO3’M34F05) includes the SHOX gene; Cosmid 51D11 (LLN0YCO3’M51D11) includes CNE6, CNE7 and markers DXYS10085; Cosmid 61E05 (LLN0YCO3’M61E05) includes CNE8 and markers DXYS10087 and DXYS10096; Cosmid 10D05 (LLN0YCO3’M10D05) includes CNE9. TEL, telomere; CEN, centromere.
the eight patients (no. 29–31) presented very small deletions of only the enhancer intervals CNE7 and CNE8, and in proband 32 only the CNE8 interval was deleted (CNEs as defined by Sabherwal et al).

MLPA analysis also demonstrated a heterozygous deletion in the PAR region in 30/58 LWS patients, showing all the peaks at a ratio 0.5 as compared to normal controls. Among the 30 microdeletions, 16 deletions encompassed the SHOX gene, whereas 14 deletions were located downstream of the SHOX gene. The smallest deletion (no. 49, fig 2) included exons 4–5 of the SHOX gene (10 kb) and was only detectable by MLPA. A comparison with the controls demonstrated that the deletion in one of the patients (no. 50) represents a polymorphism. Among the 29 microdeletions of the PAR1 region in LWS patients, one patient (no. 62) included only the enhancer interval CNE7 and CNE8.

Altogether, we identified 63 persons with copy number variations in the PAR region by screening 793 patients with short stature (735 with ISS and 58 with LWS). Sixty of these deletions were absent in a series of 100 control persons, while three were also found in the control group and had to be judged as normal variants (no. 27, 28, 50). To confirm these results with an independent method, we carried out FISH on chromosomes of several patients with small deletions, where metaphase spreads were available (no. 24–26, 29–33, 62).
Figure 3  FISH analyses of patients with idiopathic short stature. The CNE9-containing cosmid 10D05 (LLN0YC03'M'10D05) was used as a probe for FISH analysis. (A) Metaphase chromosomes from a female control with FISH signals on both X chromosomes. (B) Metaphase chromosomes from a female patient (no. 24) with a deletion on one of the chromosomes (arrows). (C) Metaphase from a male control with FISH signals on both X and Y chromosomes. (D) Metaphase from a male patient (no. 33) with a deletion on the Y chromosome (arrows) but not on the X chromosome. A reference probe residing on the long arm of the X-chromosome (cosmid P9) and a Y centromeric probe (DYZ3) were used as controls. The green signals indicate cosmids 10D05 and P9 and hybridised to opposite ends of the X chromosome; the red signal indicates probe DYZ3.

Figure 4  Summary of the spectrum of different SHOX mutations in patients with idiopathic short stature (ISS) and Leri–Weill syndrome (LWS). From all studied 735 unrelated patients with ISS, 31 are caused by SHOX-related deletions. Eight presented deletions proximal to SHOX (black) and 23 presented a SHOX gene deletion (hatched). A further five patients with ISS presented an intragenic mutation (white; 4 missense, 1 frameshift mutation; data not shown), which were initially excluded from the deletion study (total number of patients with ISS: 740). In 67 unrelated LWS, 38 are caused by SHOX-related defects: 13 presented a deletion downstream of SHOX (black), 16 presented a SHOX gene deletion (hatched) and nine presented an intragenic mutation (white; 5 missense, 3 nonsense, 1 frameshift mutation). The nine patients with intragenic mutations were initially excluded from the deletion study. In total, 4.9% of patients with ISS and 56.7% of patients with LWS are caused by point mutations or deletions of SHOX or its regulatory regions.
cases, deletions were confirmed by FISH analysis using the cosmids 51D11, 61E05 and 10D05 with a map location between 670–780 kb from the telomere (fig 3).

To further correlate the significance of one or more of the enhancer CNE elements in SHOX downstream deletions, a detailed analysis of the deletion boundaries was carried out in seven ISS cases (no. 27–33) and one LWS case (no. 62) by SNP and microsatellite analysis (supplemental fig). The smallest deletion was confined to <2 kb in proband 27 and 28 and represents a polymorphism; proband 33 had a deletion of <80 kb. In three individuals with ISS and one individual with LWS, a deletion interval smaller than 60 kb was detected that included the CNE7 and CNE8 enhancer interval. The deletion in ISS proband 32 was the smallest detectable functional variant in this series and included only the CNE8 interval.

DISCUSSION
This study was performed to establish a comprehensive view of copy number variations in patients with idiopathic short stature. The pseudautosomal region represents a block of sequence identity between the X and Y chromosomes, flanked by the telomere. It is characterised by an elevated CG content, abundant Alu repeats, and one of the highest recombination rates in the human genome.17 Deletions in the pseudautosomal region were identified in 53 of the 755 screened ISS patients (4.5%); 31 of these were not found in the screened controls. Deletions in the PAR1 region were also identified in 30 of the 58 screened LWS cases and in three of the analysed controls. As we were interested in the level and significance of enhancer deletions in patients with idiopathic short stature with regard to the overall frequency of detected mutations/deletions, the incidence of enhancer deletions of 22% was an unexpected finding, while this proportion was even higher at 34% in patients with LWS. Figure 4 gives a summary of all the SHOX gene deletions, the intragenic mutations and downstream enhancer deletions in the analysed patients with ISS and LWS. It is very likely that these high incidences are still underestimated, as we cannot rule out the possibility that some cases have been overlooked due to point mutations in enhancer sequences or deletions in other parts of this region.

Do cis-regulatory mutations in ISS or LWS make a qualitatively different contribution to disease? LWS is clinically defined by a shortened middle portion of the limb (mesomelia) leading to short stature and an abnormal alignment of the limb. The proximal SHOX region, but also has revealed that CNE8 together with CNE7, and also the deletion of the CNE8 interval alone, can be identified in patients with short stature as well as skeletal defects (no. 29–32, 62, supplemental fig). Alternatively, it also cannot be totally ruled out that the deletion of the CNE7 and CNE8 intervals may have only a minor effect, as this interval was absent in the sequence data of one recently sequenced individual; however, pedigree data were not available and SNP and microsatellite analysis, MLPA and FISH was not carried out.28 It is also possible that this part of the sequence is still inaccurate or incomplete. We also know that the phenotype in patients can be very variable (intra- and interfamiliar) and that there are individuals with SHOX deficiency and normal stature.12 14

Long range transcriptional control by enhancer sequences have been identified mostly through the analysis of patients with genetic malformations and found to reside up to hundreds of kilobases away from the genes they control.10 Three examples of long range control in limb development include enhancers in the vicinity of the mammalian Hoxd cluster27 and the Sex9 gene, defects in which cause campomelic dysplasia, a dominant skeletal malformation syndrome often associated with XY sex reversal, or Pierre Robin sequence, an important subgroup of cleft palate.22 24 Chromosome rearrangements which separate the genes from their conserved non-coding DNA elements have only been reported in a small minority of cases. The Pax6 and Shh position effect cases are further good examples of the separation of cis-regulatory elements.10 Given the findings on enhancer significance on key regulatory master genes in the literature, the high level of enhancer deletions in the SHOX gene is to our knowledge unprecedented in the human genome.

The conserved non-coding elements in the vicinity of the SHOX gene are embedded in a region with characteristics of a gene desert. Deletions encompassing more proximal or more distal pseudautosomal genes have been detected in a number of patients in our study, but this does not lead to obvious phenotypic consequences. The same holds true for a duplication of the ASMT gene which was found in two normal controls. An important diagnostic issue has, however, been raised, related to the observation that five female probands carry deletions extending into the X-specific region of the X chromosome. While these females only present short stature, their male babies could also suffer from mental retardation, chondrodysplasia punctata, ichthyosis, and Kallmann syndrome,28 depending on their exact deletion size and which X chromosomal genes are missing. For these individuals, prenatal diagnosis might represent an option.

In summary, we have applied DNA sequencing, microsatellite, FISH and MLPA analysis to detect DNA rearrangements in a large cohort of patients with idiopathic short stature of different ethnic origin. We have provided strong evidence that cis-regulatory deletions can contribute to the patient’s condition to an unexpectedly high degree. These data also re-emphasise that regulatory input can be crucial for developmental genes, most notably genes with a dynamic expression pattern. Lastly, our findings also help to optimise diagnostic options for individuals with SHOX haploinsufficiency and thus may have immediate value for patients with idiopathic short stature.

Acknowledgements: We thank Eva Decker, Claudia Durand and Claire Bacon for reading of this manuscript.

Funding: This work was supported by the Deutsche Forschungsgemeinschaft and the Land Baden-Württemberg. Jianjun Chen was supported by a grant of the postdoctoral fellowship program of the Faculty of Medicine, Heidelberg.

Competing interests: GW, DS and JD are (or were) employees of the Bioscientia Institute of Medical Genetics, WB is an employee of Eli Lilly and company. BR is a patent owner and has been reimbursed by Eli Lilly for attending and speaking at several conferences. JC, ZZ, RR, and BW have no competing interests.

Patient consent: Obtained.

Provenance and peer review: Not commissioned; externally peer reviewed.
REFERENCES

1. Gudbjartsson DF, Walters GB, Thorleifsson G, Stefansson H, Haldorsson BV, Zusmanovich P, Salem P, Thorlacius S, Gyfason A, Steinberg S, Helgadottir A, Ingason A, Steindorssdotir V, Olfsdottir DJ, Olafsdottir GH, Jonsson T, Barch-Johnson K, Hansen T, Andersen G, Jorgensen T, Pedersen O, Aben KK, Wiljes JA, Sixwinkels DW, den Heijer M, Franke B, Verbeek AL, Becker DM, Yanek LR, Becker LC, Tryggvadottir L, Rafnar T, Gulcher J, Kiemeneij LA, Kong A, Thorsteinsdottir U, Stefansson K. Many sequence variants affecting diversity of adult human height. Nat Genet 2009; 41:609–15.

2. Lettre G, Jackson AU, Gieger C, Schumacher FR, Berndt SI, Sanna S, Eyheramendy S, Voight BF, Butler JL, Guducci C, Illig T, Hackett R, Heid IM, Jacobs KB, Lyssenko V, Uda M, Diabetes Genetics Initiative, FUSION, KORA, Prostate, Lung Colorectal and Ovarian Cancer Screening Trial, Nurses’ Health Study, SardiNIA, Boehnike M, Chanock SJ, Groop LC, Hu FB, Isomaa B, Kraft P, Peltonen L, Salomaa V, Schlessinger D, Hunter DJ, Hayes RB, Abecasis GR, Wichmann HE, Mohlke KL, Hirschhorn JN. Identification of ten loci associated with height highlights new biological pathways in human growth. Nat Genet 2008; 40:584–91.

3. Weedon MN, Lange H, Lindgren CM, Wallace E, Evans DM, Mangina M, Freathy RM, Perry JR, Stevens S, Hall AS, Samani NJ, Shields B, Prokopenko I, Farrall M, Dominiczak A, Diabetes Genetics Initiative, Wellcome Trust Case Control Consortium, Johnson T, Bergmann S, Beckmann JS, Vollenweider P, Waterworth DM, Mooser V, Palmer CN, Morris AD, Ouwehand WH, Cambridge GEM Consortium, Zhao JH, Li S, Loos RJ, Barroso I, Deloukas P, Sandhu MS, Wheeler E, Soranzo N, Inouye M, Palmer RW, Reardon W, Superti-Furga A, Vassal HJ, Goodman FR, Palmer JR, Hauffa BP, van der Kamp H, Kapeller J, Crolla JA, Maloney V, Rappold G, Argente J, Campos-Barros A, Cormier-Daire V, Thomas NS, Huber C, Gorbenko del Blanco D, Aza-Carmona M, Ingason A, Lindgren CM, Wallace C, Evans DM, Mangina M, Freathy RM, Perry JR, Stevens S, Hall AS, Samani NJ, Shields B, Prokopenko I, Farrall M, Dominiczak A, Diabetes Genetics Initiative, Wellcome Trust Case Control Consortium, Johnson T, Bergmann S, Beckmann JS, Vollenweider P, Waterworth DM, Mooser V, Palmer CN, Morris AD, Ouwehand WH, Cambridge GEM Consortium, Zhao JH, Li S, Loos RJ, Barroso I, Deloukas P, Sandhu MS, Wheeler E, Soranzo N, Inouye M, Waraham NJ, Caufield M, Munroe PB, Hattersley AT, McCarthy MI, Frayling TM. Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet 2008; 40:575–83.

4. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter ED, Ross JL, Cremaschke SD, Savage MD, Wit JM, 2007 ISS Consensus Workshop participants. Consensus statement on the diagnosis and treatment of children with idiopathic short stature. J Clin Endocrinol Metab 2008; 93:4210–7.

5. Ellison JWW, Wardak Z, Young MF, Gehron Robey P, Laig-Webster M, Chiong W. PHOQ, a candidate gene for involvement in the short stature of Turner syndrome. Hum Mol Genet 1997; 6:1341–7.

6. Belin V, Cusin V, Vlot G, Gelric D, Toutain A, Moncla A, Vekemans M, Le Merrier M, Munnoch A, Cormier-Daire V. SHOX mutations in dyschondrosteosis (Leri-Weill syndrome). Nat Genet 1999; 20:93–7.

7. Shears DJ, Vassal HJ, Goodman FR, Palmer RW, Reardon W, Superti-Furga A, Scambler PJ, Winter RM. Mutation and deletion of the pseudoautosomal gene SHOX cause Leri-Weill dyschondrosteosis. Am J Hum Genet 1998; 63:67–9.

8. Kato F, Tajima T, Yokoya S, Ogata T. Transactivation function of an SOX9 downstream of SOX9 in two patients with campomelic dysplasia. Am J Hum Genet 2005; 76:652–62.

9. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muraya K, Binder G, Kirsch S, Winkelmann M, Nordase G, Heinrich U, Brunning MH, Rankie MB, Rosenthal A, Ogata T, Rappold GA. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. J Clin Endocrinol Metab 1999; 84:4613–21.

10. Kato F, Tajima T, Yokoya S, Ogata T. Downstream elements of the pseudoautosomal region: SHOX and disease. J Med Genet 2009; 46:834–893.